期刊文献+

还原型谷胱甘肽联合水飞蓟素治疗酒精性肝病的疗效观察 被引量:1

The silymarin cobined with glutathione treatment of chronic alcoholic liver disease
下载PDF
导出
摘要 目的观察还原型谷胱甘肽联合水飞蓟素治疗慢性酒精性肝病的临床疗效。方法将128例慢性酒精性肝病患者随机分为两组,对照组64例,观察组64例。对照组给予还原型谷胱甘肽1.2g静脉滴注1次/d;观察组在对照组基础上加用水飞蓟素140mg,2次/d口服。分别于治疗前及治疗后1个月检测两组患者肝功能指标ALT、AST、GGT、TBIL及肝纤维化指标HA、PCⅢ、IV-C等,评价其疗效。结果治疗1个月后,观察组显效52例(81.25%),有效8例(12.5%),无效4例(6.25%);对照组显效25例(39.06%),有效15例(23.43%),无效24例(37.50%);两组比较总有效率、肝功能比较,差异有统计学意义(P<0.05)。结论水飞蓟素联合还原型谷胱甘肽治疗慢性酒精性肝病疗效显著,两药联合优势互补。 Objective The therapeutic effect of the silymarin combined with glutathione on chronic alcoholic liver disease was studied. Methods 128 patients with chronic alcoholic liver disease were randomly divided into two groups. Control group 64 cases were treated with reduced glutathione 600 mg once a day.The observation group added Silymarin 140 mg bid po. On the basis of the control group. Respectively,liver function and liver fibrosis index were tested between the two groups before treatment and after 1 month treatment in patients. Results After one month of treatment, the observation group,52 cases (81.25%) were markedly effective,8 patients (12.5%) were effective, 4 cases (6.25%) were ineffective;the control group, 25 cases (39.06%) were markedly effective, 15 cases (23.43%) were effective, 24 cases (37.50%) were ineffective; total efficiency in the group (P0.05), comparison of liver function(P0.05),the difference was statistically significant.Conclusion Silymarin combined with glutathione can significantly improved clinical treatment effect of chronic alcoholic liver disease,synergistic effect were existed between the two drugs.
作者 于清英
出处 《中国实用医药》 2012年第34期21-22,共2页 China Practical Medicine
关键词 水飞蓟素 还原型谷胱甘肽 慢性酒精性肝病 治疗结果 Silymarin Glutathione Alcoholic liver disease Treatment outcome
  • 相关文献

参考文献7

  • 1马晓茜.酒精性肝病的发病机制与药物治疗.中外健康文摘,2011,8:102-104.
  • 2中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊断标准[J].中华肝脏病杂志,2003,11(2):72-72. 被引量:585
  • 3Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..酒精性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):164-166. 被引量:271
  • 4王宝恩,尹珊珊.酒精性肝病的流行病学[J].中华肝脏病杂志,2001,9(5):312-312. 被引量:65
  • 5Department of Gastroenterology and Hepatology, Loma Linda Uni- versity Medical Center, Loma Linda, CA 92354, United States. World Journal OF Gastroenterology,2010,16 ( 39 ) 4905-4912.
  • 6H. Ahmadi-Ashtiani A. Allameh. Inhibition of cyclooxygenase-2 and inducible nitric oxide synthase by silymarin in proliferating mes- enchymal stem cells : comparison with glutathione modifiers, springer. J Nat Med, 2012,66 : 85-94.
  • 7DetaiUe D, Sanchez C, Sanz N, et al. Interrelation between the in- hibition of glycolytic flux by silibinin and the lowering of mitochon- drial ROS production in perifused rat hepatocytes. Life Sci, 2008, 82 : 1070-1076.

二级参考文献15

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 2Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861.
  • 3Sanyal AJ.American Gastroenterological Association technical review on nonalcoholic fatty liver disease.Gastroenterology,2002,123:1705-1725.
  • 4Graif M,Yanuka M,Baraz M,et al.Quantitative estimation of attenuation in ultrasound video images:correlation with histology in diffuse liver disease.Invest Radiol,2000,35:319-324.
  • 5Ataseven H,Yildrim MH,Yalniz M,et al.Correlation between computerized tomographic findings and histopathologic grade/stage in non-alcoholic steatohepatitis.J Hepatol,2003,38(Suppl 2):A4177.
  • 6Farrell GC,George J,Pauline de la M.Hall,et al,eds.Fatty liver diseas:NASH and related disorders.Oxford:Blackwell Publishing,2005.159-207.
  • 7McCullough AJ,O'Connor JF.Alcoholic liver disease:proposed recommendations for the American College of Gastroenterology.Am J Gastroenterol,1998,93:2022-2036.
  • 8Stickel F,Hoehn B,Schuppan D,et al.Review article:Nutritional therapy in alcoholic liver disease.Aliment Pharmacol Ther,2003,18:357-373.
  • 9Mathurin P,Mendenhall CL,Carithers RLJr,et al.Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH):individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH.J Hepatol,2002,36:480-487.
  • 10Imperiale TF,O'Connor JB,McCullough AJ.Corticosteroids are effective in patients with severe alcoholic hepatitis.Am J Gastroenterol,1999,94:3066-3068.

共引文献899

同被引文献23

  • 1田丽艳,陆伦根.2012欧洲肝病学会临床实践指南:酒精性肝病的治疗[J].中国医学前沿杂志(电子版),2012,4(9):64-71. 被引量:8
  • 2Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol,2013,28 (Suppl 1): 11-17.
  • 3Schwartz JM,Reinus JF. Prevalence and natural history of al- coholic liver disease. Clin Liver Dis,2012,16(4):659-666.
  • 4Kostek HI,Szponar J,Tchorz M,et al. Silibinin and its hepato- protective action from the perspective of a toxicologist. Przegl Lek,2012,69(8) :541-543.
  • 5Dou X,Shen C,Wang Z,et al. Protection of nicotinic acid against oxidative stress-induced cell death in hepatocytes contributes to its beneficial effect on alcohol-induced liver injury in mice. J Nutr Biochem,2013,24(8):1520-1528.
  • 6Summa KC,Voigt RM,Forsyth CB,et al. Disruption of the circadian clock in mice increases intestinal permeability and promotes alcohol-induced hepatic pathology and inflammation. PLoS One,2013,8(6) : e67102.
  • 7Testino G,Leone S,Ansaldi F,et al. Silymarin and S-adenosyl- L-methionine (SAMe):two promising pharmacological agents in case of chronic alcoholic hepathopathy. A review and a point of view. Minerva Gastroenterol Dietol,2013,59(4):341-356.
  • 8Zhang W,Hong R,Tian T. Silymarin's protective effects and possible mechanisms on alcoholic fatty liver for rats. Biomol Ther (Seoul), 2013,21 (4):264-269.
  • 9Iakimchuk GN,Gendrikson LN. Study of clinical efficiency of essential phospbolipids and silymarin combination in nonalco- holic and alcoholic steatohepatitis. Eksp Klin Gastroenterol, 2011, (7):64-69.
  • 10Berger J,Kowdley KV. Is silymarin hepatoprotective in alco- holic liver disease J Clin Gastroenterol, 2003,37(4):278-279.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部